Amgen scored the big win for its PCSK9 drug Repatha (evolocumab). The FDA announced Thursday afternoon that it has given Amgen a green light on marketing the PCSK9 cholesterol drug, opening the door to what will likely prove a blockbuster market.
Harpreet Singh, the CSO and co-founder of Germany's Immatics Biotechnologies, has been splitting his time between Germany and Houston, setting up a new biotech company that will collaborate with top researchers at MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline. Read more >>
Welcome to the latest edition of our weekly EuroBiotech Report. Oncology has long been a strong suit for Norway. With a 60-year old cancer registry, the legacy of breakout biotech success Algeta and a clutch of immuno-oncology upstarts to its name, the country has the credentials to make an impact on R&D. This week, a long-gestating attempt to corral these resources into a joined-up assault on cancer got underway with the opening of the NOK 1 billion ($120 million) Oslo Cancer Cluster Innovation Park. Across the border in Sweden, investors cheered the publication of long-term data from a trial of Swedish Orphan Biovitrum's (STO:SOBI) Biogen ($BIIB)-partnered hemophilia B drug, Alprolix. And more >>
23andMe named Dean Schorno as its CFO and operations head this week, a role in which he'll oversee the company's global financial and clinical laboratory operations. Schorno most recently served as CFO for Adaptive Biotechnologies, where he was responsible for all financial operations and facilities management. Prior to Adaptive, Schorno spent 13 years at Genomic Health, where he served as both vice president of operations and chief financial officer. Read more >>
POPULAR COMMENT THREADS
There are a lot of reasons why oncologists aren't exactly brimming with excitement at the idea of getting their hands on Eli Lilly's lung cancer drug necitumumab.
Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.
A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, a stem cell researcher who went from being featured on the front page of the New York Times to fending off accusations of misconduct.
The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. The FDA's suggested solution: Take the generic name and add four random letters to make it a unique identifier.
From Our Sister Sites
Engineer Scott Leibrand and diabetes patient Dana Lewis have created an artificial pancreas, via years of constant experimentation and iterative upgrades.
Insulet said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance. In July, the company issued a voluntary recall of more than 400,000 OmniPod Insulin Management Systems, which are wearable insulin pumps.